We announce the appointment of John L Brooks III

John L Brooks III is an expert in the field of diabetes, and will be a key advisor to the scale up of the business, supporting the company’s mission to make Noctura 400 sleep mask available to as many diabetic patients with eye disease as is humanly possible.

Over a career spanning 43 years, Mr. Brooks was the Chair as well as the President and CEO of the Joslin Diabetes Center in Boston USA for over 10 years. The Joslin Diabetes Center (affiliated with the Harvard Medical School) is the world’s largest and most important diabetic research centre. Mr. Brooks has led international teams focused on healthcare private equity investment.

Mr. Brooks is a well-known life sciences executive. He has co-founded eight life sciences companies. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm. He is also the co-founder of Insulet Corporation (PODD).

“Having been in the sector for many years and then being introduced to the Noctura 400 eye mask, I was delighted to be able to join a team that is going to have such a major and fundamental impact on the life of patients with diabetic retinopathy and diabetic macular edema. In countries where therapies can be afforded, the treatment regime is harsh and requires injections into the eyeball, that at best defer blindness. The solution that Noctura 400 offers not only provides a simple and affordable solution for the global market, but its non-invasive nature offers a solution to diabetic blindness.” Mr. Brooks said.

Rickard Kirk, CEO commented “Having the breadth and depths of John’s skills will supercharge the company to achieving its mission to make the Noctura 400 available to anyone with diabetic eye disease across the globe. We offer an affordable and simple to use solution that we continue to innovate around, enabling the healthcare professional, patient and company to address the impact of this horrific disease and the loss of sight.”